A Randomized, Double-Blind, Parallel-Group Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of LY01008, a Candidate Bevacizumab Biosimilar, with Its Reference Product Avastin® in Healthy Chinese Male Subjects
Expert Opinion on Biological Therapy（2021）
Key words
LY01008,bevacizumab,biosimilar,pharmacokinetics,safety,immunogenicity
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined